Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy

NCT07306286 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Adenocarcinoma Locally Advanced

Interventions

RADIATION: Cryoablation
DRUG: Dual-Function Antibody PD-1/CTLA-4

Sponsor

Ruijin Hospital